Tango Therapeutics (TNGX) to Release Quarterly Earnings on Monday

Tango Therapeutics (NASDAQ:TNGX) is anticipated to post its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect the company to announce earnings of ($0.3182) per share and revenue of $0.50 million for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, March 5, 2026 at 9:00 AM ET.

Tango Therapeutics (NASDAQ:TNGX) last issued its quarterly earnings data on Thursday, March 5th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.02. Tango Therapeutics had a negative net margin of 151.15% and a negative return on equity of 50.30%. On average, analysts expect Tango Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Tango Therapeutics Price Performance

NASDAQ:TNGX opened at $19.42 on Monday. Tango Therapeutics has a one year low of $1.03 and a one year high of $19.81. The company has a market cap of $2.77 billion, a PE ratio of -22.32 and a beta of 1.76. The firm’s 50 day simple moving average is $13.49 and its 200 day simple moving average is $10.26.

Analysts Set New Price Targets

TNGX has been the subject of several analyst reports. Jefferies Financial Group reaffirmed a “buy” rating and set a $18.00 price target on shares of Tango Therapeutics in a research note on Thursday, March 5th. Guggenheim increased their price objective on Tango Therapeutics from $18.00 to $20.00 and gave the company a “buy” rating in a report on Friday, March 6th. Mizuho raised their target price on Tango Therapeutics from $19.00 to $20.00 and gave the stock an “outperform” rating in a research report on Wednesday, March 11th. Wedbush lifted their target price on Tango Therapeutics from $15.00 to $19.00 and gave the stock an “outperform” rating in a report on Friday, March 6th. Finally, Wall Street Zen lowered Tango Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. Nine analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $19.50.

Insider Activity

In related news, CFO Daniella Beckman sold 10,317 shares of the business’s stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $12.26, for a total transaction of $126,486.42. Following the transaction, the chief financial officer owned 184,297 shares in the company, valued at $2,259,481.22. The trade was a 5.30% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Barbara Weber sold 30,519 shares of the stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $12.26, for a total transaction of $374,162.94. Following the transaction, the director directly owned 1,629,254 shares in the company, valued at approximately $19,974,654.04. This represents a 1.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 133,884 shares of company stock worth $1,724,622 in the last quarter. 7.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Tango Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in TNGX. XTX Topco Ltd acquired a new stake in shares of Tango Therapeutics in the 4th quarter valued at about $335,000. VARCOV Co. acquired a new position in Tango Therapeutics during the 4th quarter worth approximately $261,000. Virtus Investment Advisers LLC boosted its holdings in Tango Therapeutics by 26.3% in the fourth quarter. Virtus Investment Advisers LLC now owns 28,452 shares of the company’s stock worth $252,000 after acquiring an additional 5,920 shares in the last quarter. Tudor Investment Corp ET AL boosted its holdings in Tango Therapeutics by 27.4% in the fourth quarter. Tudor Investment Corp ET AL now owns 68,251 shares of the company’s stock worth $605,000 after acquiring an additional 14,679 shares in the last quarter. Finally, Sphera Funds Management LTD. acquired a new stake in Tango Therapeutics in the fourth quarter valued at approximately $4,825,000. Institutional investors own 78.99% of the company’s stock.

Tango Therapeutics Company Profile

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.